Africa and Middle East Cardiovascular Epidemiological Study (ACE)
2021年2月17日 更新者：Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Prevalence of Cardiovascular Risk Factors in Patients Attending General Practice Clinics in Selected Countries in the Africa and The Middle East Region
This is a cross-sectional, epidemiological study to determine the prevalence of cardiovascular risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension in patients attending General Practice clinics in the Africa and Middle East region.
A total of 4300 patients will be evaluated.
In patients who are found to have previously been diagnosed with cardiovascular (CV) risk factors such as dyslipidemia or hypertension, the level of control of their respective conditions will also be evaluated.
研究概览
详细说明
This is a cross-sectional, epidemiological study. In the course of this study, 4,300 persons from general practice, and other non specialist clinics of selected countries of the Africa and Middle East region, will be evaluated for the presence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension. The degree of control of hypertension and dyslipidaemia in those previously diagnosed with these conditions will also be assessed. All medications used for CV risk factor control will also be ascertained.
Patient evaluation will be done by physicians in charge of the selected clinics (who will be trained for case report forms completion) over one visit, through history taking, clinical examination as well as laboratory investigations. Every fifth patient seen on a particular day, fulfilling the inclusion and exclusion criteria would be included in the study.
研究类型
观察性的
注册 (实际的)
4386
联系人和位置
本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。
学习地点
-
-
-
Accra、加纳
- Pfizer Investigational Site
-
Jachie-Ashanti、加纳
- Pfizer Investigational Site
-
Kumasi、加纳
- Pfizer Investigational Site
-
Sogakope V/R、加纳
- Pfizer Investigational Site
-
Takoradi、加纳
- Pfizer Investigational Site
-
-
-
-
-
Kwa-Zulu Natal、南非、4091
- Pfizer Investigational Site
-
Rondebosch、南非、7700
- Pfizer Investigational Site
-
-
Gauteng
-
Halfway House、Gauteng、南非、1685
- Pfizer Investigational Site
-
-
Kwazulu-natal
-
Sydenham, Durban、Kwazulu-natal、南非、4091
- Pfizer Investigational Site
-
-
Limpopo
-
Mokopane、Limpopo、南非、0600
- Pfizer Investigational Site
-
Sheshego、Limpopo、南非、0742
- Pfizer Investigational Site
-
-
Pretoria
-
Mamelodi East、Pretoria、南非、0122
- Pfizer Investigational Site
-
-
-
-
-
Bafoussam、喀麦隆
- Pfizer Investigational Site
-
Mbandjock、喀麦隆
- Pfizer Investigational Site
-
Njombe、喀麦隆
- Pfizer Investigational Site
-
Soa、喀麦隆
- Pfizer Investigational Site
-
-
Cite Verte
-
Yaounde、Cite Verte、喀麦隆
- Pfizer Investigational Site
-
-
Deido
-
Douala、Deido、喀麦隆
- Pfizer Investigational Site
-
-
-
-
-
Alexandria、埃及
- Pfizer Investigational Site
-
Cairo、埃及
- Pfizer Investigational Site
-
Shiben Al Kom、埃及
- Pfizer Investigational Site
-
Tanta、埃及
- Pfizer Investigational Site
-
-
-
-
-
Kebemer、塞内加尔
- Pfizer Investigational Site
-
Kedoungou、塞内加尔
- Pfizer Investigational Site
-
Saint Louis、塞内加尔
- Pfizer Investigational Site
-
Ziguinchor、塞内加尔
- Pfizer Investigational Site
-
-
Nabil Choucair
-
Dakar、Nabil Choucair、塞内加尔
- Pfizer Investigational Site
-
-
Ouakam
-
Dakar、Ouakam、塞内加尔
- Pfizer Investigational Site
-
-
-
-
-
Abuja, FCT、尼日利亚
- Pfizer Investigational Site
-
Abuja, Garki、尼日利亚
- Pfizer Investigational Site
-
Calabar、尼日利亚
- Pfizer Investigational Site
-
Enugu、尼日利亚
- Pfizer Investigational Site
-
Keffi, Nassarawa、尼日利亚
- Pfizer Investigational Site
-
-
-
-
-
Dammam、沙特阿拉伯
- Pfizer Investigational Site
-
Jeddah、沙特阿拉伯
- Pfizer Investigational Site
-
Jeddah 21573、沙特阿拉伯
- Pfizer Investigational Site
-
Makkah、沙特阿拉伯
- Pfizer Investigational Site
-
Riyadh、沙特阿拉伯
- Pfizer Investigational Site
-
Riyadh、沙特阿拉伯、11584
- Pfizer Investigational Site
-
Yanbu、沙特阿拉伯
- Pfizer Investigational Site
-
-
-
-
-
Adailiya、科威特
- Pfizer Investigational Site
-
Fahaheel、科威特
- Pfizer Investigational Site
-
Kuwait、科威特
- Pfizer Investigational Site
-
Mishref、科威特
- Pfizer Investigational Site
-
Qadesya、科威特
- Pfizer Investigational Site
-
Yarmouk、科威特
- Pfizer Investigational Site
-
-
-
-
-
Ariana、突尼斯、2073
- Pfizer Investigational Site
-
Bouficha、突尼斯、4010
- Pfizer Investigational Site
-
Messaadine、突尼斯、4013
- Pfizer Investigational Site
-
Sfax、突尼斯、3013
- Pfizer Investigational Site
-
Tunis、突尼斯、1000
- Pfizer Investigational Site
-
Zaghouan、突尼斯、1100
- Pfizer Investigational Site
-
-
-
-
-
Amman、约旦
- Pfizer Investigational Site
-
Irbid、约旦
- Pfizer Investigational Site
-
Salt、约旦
- Pfizer Investigational Site
-
-
-
-
-
Chongoria、肯尼亚、60401
- Pfizer Investigational Site
-
Nairobi、肯尼亚、00508
- Pfizer Investigational Site
-
-
-
-
-
Alger、阿尔及利亚、16015
- Pfizer Investigational Site
-
Bejaja、阿尔及利亚、6000
- Pfizer Investigational Site
-
Djelfa、阿尔及利亚、17000
- Pfizer Investigational Site
-
Laghouat、阿尔及利亚
- Pfizer Investigational Site
-
M'Sila、阿尔及利亚
- Pfizer Investigational Site
-
Relizane、阿尔及利亚、48000
- Pfizer Investigational Site
-
Saida、阿尔及利亚、20000
- Pfizer Investigational Site
-
Tebessa、阿尔及利亚
- Pfizer Investigational Site
-
Tlemcen、阿尔及利亚、13000
- Pfizer Investigational Site
-
-
-
-
-
Abu Dhabi、阿拉伯联合酋长国
- Pfizer Investigational Site
-
Al Ain、阿拉伯联合酋长国
- Pfizer Investigational Site
-
Dubai、阿拉伯联合酋长国
- Pfizer Investigational Site
-
Ras Al Khaima、阿拉伯联合酋长国
- Pfizer Investigational Site
-
-
-
-
-
Beirut、黎巴嫩
- Pfizer Investigational Site
-
Jbeil, Lebanon、黎巴嫩
- Pfizer Investigational Site
-
Jounieh、黎巴嫩
- Pfizer Investigational Site
-
Tripoli、黎巴嫩
- Pfizer Investigational Site
-
-
参与标准
研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
是的
有资格学习的性别
全部
取样方法
概率样本
研究人群
Subject selection would be from clinics in a primary care setting
描述
Inclusion Criteria:
- Adult aged 18 or above
Exclusion Criteria:
- Pregnant women and/or lactating mothers
- Subjects presenting with any life threatening disease/condition
学习计划
本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。
研究是如何设计的？
设计细节
研究衡量的是什么？
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Prevalence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension
大体时间：At the time of the first visit
|
At the time of the first visit
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Compare the prevalence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension in the urban and rural population.
大体时间：At the time of the first visit
|
At the time of the first visit
|
|
Compare the prevalence of CV risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension in the male and female population.
大体时间：At the time of the first visit
|
At the time of the first visit
|
|
Stratifying the prevalence of CV risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension by age groups.
大体时间：At the time of the first visit
|
At the time of the first visit
|
|
Ascertain the level of blood pressure and lipids' control as per the European Society of Cardiology (ESC) guidelines in patients who have been previously diagnosed as hypertensive or dyslipidaemic.
大体时间：At the time of the first visit
|
At the time of the first visit
|
|
Ascertain the most commonly used medications in those that have been previously diagnosed as diabetic, hypertensive or dyslipidaemic.
大体时间：At the time of the first visit
|
At the time of the first visit
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Hamoui O, Omar MI, Raal FJ, Rashed W, Kane A, Alami M, Abreu P, Mashhoud W, Alsheikh-Ali AA. Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study. BMC Cardiovasc Disord. 2019 Mar 15;19(1):61. doi: 10.1186/s12872-019-1034-2.
- Brouri M, Ouadahi N, Nibouche D, Benabbas Y, El Hassar M, Bouraoui S, Abad N, Abreu PC, Ikardouchene L. [Cardiovascular risk factors in Algeria. Analysis of the subgroup from the "Africa/Middle East Cardiovascular Epidemiological" Study]. Ann Cardiol Angeiol (Paris). 2018 Apr;67(2):61-66. doi: 10.1016/j.ancard.2018.01.003. Epub 2018 Mar 9. French.
- Raal FJ, Alsheikh-Ali AA, Omar MI, Rashed W, Hamoui O, Kane A, Alami M, Abreu P, Mashhoud WM. Cardiovascular risk factor burden in Africa and the Middle East across country income categories: a post hoc analysis of the cross-sectional Africa Middle East Cardiovascular Epidemiological (ACE) study. Arch Public Health. 2018 Feb 12;76:15. doi: 10.1186/s13690-018-0257-5. eCollection 2018.
- Ahmed AM, Hersi A, Mashhoud W, Arafah MR, Abreu PC, Al Rowaily MA, Al-Mallah MH. Cardiovascular risk factors burden in Saudi Arabia: The Africa Middle East Cardiovascular Epidemiological (ACE) study. J Saudi Heart Assoc. 2017 Oct;29(4):235-243. doi: 10.1016/j.jsha.2017.03.004. Epub 2017 Mar 14.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2011年7月1日
初级完成 (实际的)
2012年4月1日
研究完成 (实际的)
2012年4月1日
研究注册日期
首次提交
2010年11月12日
首先提交符合 QC 标准的
2010年11月16日
首次发布 (估计)
2010年11月18日
研究记录更新
最后更新发布 (实际的)
2021年2月18日
上次提交的符合 QC 标准的更新
2021年2月17日
最后验证
2021年2月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.